Clinical Trials

There are currently FOUR phase I clinical trials investigating the use of a new class of drug, termed BET inhibitors, 
that directly target the BRD4-NUT protein that drives the growth of NUT midline carcinoma.
Information about the trials can be found at the following links:

https://www.clinicaltrials.gov/ct2/show/NCT01587703?term=NMC&rank=1
**A new site for this trial will open soon in Australia located at Monash Health in Melbourne, Australia. Please contact the principal investigator, Dr. Arun Azad (arun.azad@monash.edu), for information**

https://clinicaltrials.gov/ct2/show/NCT01987362?term=tensha&rank=1

https://clinicaltrials.gov/ct2/show/NCT02698176?term=nut+midline+carcinoma&rank=3

https://clinicaltrials.gov/ct2/show/NCT02711137?term=nut+midline+carcinoma&rank=6


There is a clinical trial investigating the use of a recommended Phase 2 dose of a dual PI3 kinase/ HDAC inhibitor drug, CUDC-907, that has been shown to have potent activity against cultured NMC cells.
Information about this trial can be found at the following link:

https://clinicaltrials.gov/ct2/show/NCT02307240?term=cudc-907&rank=2

For inquiries regarding entry into these trials, please contact Dr. Chris French at cfrench@partners.org , tel 617 525-4415.

Copyright © 2011 International NUT Midline Carcinoma Registry. All Rights Reserved.